JPWO2021062298A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021062298A5 JPWO2021062298A5 JP2022519782A JP2022519782A JPWO2021062298A5 JP WO2021062298 A5 JPWO2021062298 A5 JP WO2021062298A5 JP 2022519782 A JP2022519782 A JP 2022519782A JP 2022519782 A JP2022519782 A JP 2022519782A JP WO2021062298 A5 JPWO2021062298 A5 JP WO2021062298A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- biomarkers
- papp
- pregnancy
- glycocalyx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962907389P | 2019-09-27 | 2019-09-27 | |
| US62/907,389 | 2019-09-27 | ||
| PCT/US2020/052912 WO2021062298A1 (en) | 2019-09-27 | 2020-09-25 | Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022549373A JP2022549373A (ja) | 2022-11-24 |
| JPWO2021062298A5 true JPWO2021062298A5 (https=) | 2023-10-11 |
| JP2022549373A5 JP2022549373A5 (https=) | 2023-10-11 |
| JP7689518B2 JP7689518B2 (ja) | 2025-06-06 |
Family
ID=75166872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022519782A Active JP7689518B2 (ja) | 2019-09-27 | 2020-09-25 | グリコカリックス破壊の多因子オントロジーによる疾患をターゲティングしたバイオマーカーパネル |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220390454A1 (https=) |
| EP (1) | EP4034164A4 (https=) |
| JP (1) | JP7689518B2 (https=) |
| AU (1) | AU2020356626A1 (https=) |
| CA (1) | CA3155843A1 (https=) |
| IL (1) | IL291667A (https=) |
| WO (1) | WO2021062298A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| US12105099B2 (en) | 2021-04-28 | 2024-10-01 | Diotex Diagnostics, Llc | Methods and devices for quantitatively estimating syndecan-1 |
| CN115389773A (zh) * | 2022-09-22 | 2022-11-25 | 无锡市第二人民医院 | 糖萼脱落标志物在诊断和防治初发的2型糖尿病肾病早期肾损伤的应用 |
| WO2025049608A1 (en) * | 2023-08-28 | 2025-03-06 | Calroyhealth Sciences, Llc | Compositions and methods to protect and enhance structural and functional integrity of the intestinal glycocalyx |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2437491T3 (es) * | 2003-10-10 | 2014-01-10 | Alchemia Oncology Pty Limited | Modulación de la síntesis y degradación de hialuronano en el tratamiento de enfermedad |
| CA2511269A1 (en) * | 2004-07-07 | 2006-01-07 | F. Hoffmann-La Roche Ag | Multimarker panel based on p1gf for diabetes type 1 and 2 |
| EP2302395B1 (en) * | 2006-06-07 | 2015-04-15 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| WO2008080030A2 (en) * | 2006-12-22 | 2008-07-03 | Abbott Laboratories | Cardiovascular autoimmune disease panel and methods of using same |
| WO2011115783A1 (en) * | 2010-03-15 | 2011-09-22 | Oregon Health & Science University | Methods for assessing the risk of cardiovascular disease |
| WO2012106152A1 (en) * | 2011-02-03 | 2012-08-09 | Abbott Laboratories | Methods of prognosis and diagnosis in chronic heart failure |
| US9086412B2 (en) * | 2012-12-31 | 2015-07-21 | University Of Louisville Research Foundation, Inc. | Extracellular vesicle-associated protein markers of cancer |
| EP2965088B1 (en) * | 2013-03-04 | 2018-12-05 | IQ Products B.V. | Prognostic marker to determine the risk for early-onset preeclampsia |
| WO2016123163A2 (en) * | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| WO2016126662A1 (en) * | 2015-02-03 | 2016-08-11 | Kardiatonos, Inc. | Compounds for the prevention and treatment of vascular disease |
| WO2016164534A1 (en) * | 2015-04-09 | 2016-10-13 | Kardiatonos, Inc. | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage |
| WO2016176089A1 (en) * | 2015-04-29 | 2016-11-03 | Kardiatonos, Inc. | Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage |
| WO2017136652A1 (en) * | 2016-02-04 | 2017-08-10 | Tarveda Therapeutics, Inc. | Stapled peptide conjugates and particles |
| JP7420557B2 (ja) * | 2017-03-07 | 2024-01-23 | オルト－クリニカル ダイアグノスティックス インコーポレイテッド | 分析物を検出するための方法 |
-
2020
- 2020-09-25 CA CA3155843A patent/CA3155843A1/en active Pending
- 2020-09-25 JP JP2022519782A patent/JP7689518B2/ja active Active
- 2020-09-25 EP EP20868963.8A patent/EP4034164A4/en active Pending
- 2020-09-25 US US17/762,703 patent/US20220390454A1/en active Pending
- 2020-09-25 WO PCT/US2020/052912 patent/WO2021062298A1/en not_active Ceased
- 2020-09-25 AU AU2020356626A patent/AU2020356626A1/en not_active Abandoned
-
2022
- 2022-03-24 IL IL291667A patent/IL291667A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7689518B2 (ja) | グリコカリックス破壊の多因子オントロジーによる疾患をターゲティングしたバイオマーカーパネル | |
| Chakrapani et al. | α-Gal present on both glycolipids and glycoproteins contributes to immune response in meat-allergic patients | |
| US8759095B2 (en) | Diagnostic and therapeutic tools for diseases altering vascular function | |
| US8232295B2 (en) | Treating vascular events with statins by inhibiting PAR-1 and PAR-4 | |
| KR20210013297A (ko) | pKal 매개 장애의 평가, 검정 및 치료 | |
| US12421298B2 (en) | Compositions and methods for evaluating anticoagulant therapeutic efficacy | |
| Janion-Sadowska et al. | Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban | |
| Natorska et al. | Impaired fibrinolysis is associated with the severity of aortic stenosis in humans | |
| JP6198277B2 (ja) | 血液凝固促進に使用するための化合物 | |
| CA3012985A1 (en) | Biomarkers of vascular disease | |
| Sun et al. | Plasma activity of endothelial lipase impacts high-density lipoprotein metabolism and coronary risk factors in humans | |
| JPWO2021062298A5 (https=) | ||
| EP3117356B1 (en) | Diagnostic marker for treatment of cerebral ischemia | |
| US20220288110A1 (en) | Drug treatment and biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption | |
| US8852879B2 (en) | Materials and methods for the detection of nitrated fibrinogen | |
| US20090042800A1 (en) | Assay | |
| US20080138913A1 (en) | Composition for Prevention, Treatment, and Diagnosis of Chronic Inflammatory Airway Diseases | |
| US20210346482A1 (en) | Substances, vaccines and methods for diagnosing and reducing incidences of transplant rejection | |
| Duering et al. | Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke | |
| ES2295475T3 (es) | Mutantes marburg i de la proteasa activante del factor vii (fsap) como factor de riesgo de trombosis arterial. | |
| Zanon et al. | Prevalence of antiphospholipid antibodies and lupus anticoagulant in juvenile patients with objectively documented deep-vein thrombosis | |
| Ortel et al. | Antiphospholipid Syndrome | |
| JP2020524283A (ja) | 急性非代償性心不全（ａｄｈｆ）患者が凝固亢進状態を示すかどうかを同定するための方法 | |
| US20080299045A1 (en) | Composition for Prevention, Treatment, and Diagnosis of Chronic Obstructive Pulmonary Disease (Copd) | |
| Rounds | Anticoagulation in Antiphospholipid Antibody Syndrome |